本日は『内科レジデントの鉄則』セミナーでした！100名を超える方に御参加頂き感謝です。 森先生、レジデントの小松先生、中川先生、なにより医学書院の皆様、ご参加頂いた皆様、大変貴重な機会をありがとうございました！ 有名なlibraryは大変に趣きがあり大変素敵な空間でした。 #医学書院

明日から参加しますー！ 心リハ学会は初めてなので楽しみ！ みなさん宜しくお願いします！ #JACR2024

大変貴重な機会を頂いて、心リハ学会参加してきました！ 目から鱗の話ばかりで、勉強させて頂き、自分たちも次に繋がる取り組みを続けていけたらと思います。皆さまお疲れ様でした！ #心リハ #JACR2024 #神戸

Excited to share our latest project! First attempt to quantify the quality of death in acute CVD using GDI. A significant step forward in this field. Sincere thanks and respect to all co-authors! 水野篤＠心臓の医者✨✨ Please check it out here! bmcpalliatcare.biomedcentral.com/articles/10.11… #CVD #Good_death

【長文すいません。感謝と論文の背景紹介です。循環器緩和に興味がない方は飛ばしてください （論文はチェックしてもらえたらうれしいです）】 本文はこちら👉👉 bmcpalliatcare.biomedcentral.com/articles/10.11… ”遺族調査”という皆さん聞きなれない内容かと思います 極めて多くの方々に協力・ご指導いただいた研究で、

The DECISION QFR Trial shows QFR is a viable alternative to FFR for revascularization in multivessel disease, offering substantial agreement in treatment decisions and shorter procedure times. #EAPCI #QFR eurointervention.pcronline.com/article/quanti…

【医療の質：Quality indicatorのページ本日公開】 これまで書籍でおなじみいただいておりました、 聖路加QIですが、なんと！！ 【!!無料!!】で見れてしまうようになりました 病院公式ページの中にありますので ぜひぜひご確認ください！！ 👉👉qi.luke.ac.jp/2023/ 聖路加国際大学広報課

How has COVID-19 affected CV care in the Asian-Pacific?japscjournal.com/articles/cardi…　 1/ Practice: Patient n dropped in 2020 but later ⤴️ 2/ Disrupted training: Non-CV workload⤴️, Family/research time⤵️ 3/ Interests in Long COVID research⤴️ #COVID19 #APSC Atsushi Mizuno, MD, PhD, MBA, MHCI

NEW ISSUE OUT 🔉 ✅ State-of-the-art review on antithrombotic therapy in transcatheter structural heart intervention; ✅ Concomitant LAAO and mitral transcatheter edge-to-edge repair; ✅ Off-hours effects in STEMI and cardiogenic shock; ✅ New atrial fibrillation in ACS

Happy to share our new project from J-PVAD🗾 ✅"Off-hours effect🌃" persists in STEMI-CS patients treated with Impella ✅Longer DTB/DTU time in Off-hours ✅Need to enhance off-hours medical services eurointervention.pcronline.com/article/impact… Thanks to all co-authors and registry members! 水野篤＠心臓の医者✨✨

Does the off-hours effect impact patients with #STEMI and treatment with #Impella? 🫀 Prof. Thomas Engstrøm and I had the honor of writing an Editorial in the newest issue of EuroIntervention to the newly published important insights from the J-PVAD registry 💡 #CardioTwitter

Our study on age-related Left-digit bias (LDB) in OHCA from JCS-ReSS🗾 is out! 🤳➡️dx.plos.org/10.1371/journa… 📣Checked for LDB 📣LDB may not impact urgent medical decision-making in OHCA situations🚑 Sincere thanks to the registry team and all co-authors! 水野篤＠心臓の医者✨✨ Tetsuya Matoba, FJCS, FAHA, FESC

ロンドンでしっかり勉強したいと思います！ 参加される皆様よろしくお願い致します！！ #ESCCongress #London

これはワクワクしますね！ #ESCCongress #London #Cardiology

The OCEANIC-AF randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with apixaban therapy among patients with atrial fibrillation. Full trial results: nej.md/473TRdc #ESCardio

Treatment with SGLT2 inhibitors after myocardial infarction in people with T2 diabetes associated with a lower rate of cardiovascular events. SWEDEHEART study thelancet.com/journals/lanep…

Is it time to go back to the drawing board with competing risks/deaths in RCTs? See practical recommendations for handling competing risks in future trials: bit.ly/3ZgbViu #JACC #CVD Dr. Deepak L. Bhatt Gregg W. Stone MD

This debate explores the pros and cons of using percutaneous transvalvular microaxial flow pumps for patients with infarct-related cardiogenic shock. While the DanGer Shock trial showed a significant reduction in mortality using these pumps, concerns remain around complications